化合物信息

Drug Groups

approved

Description

A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma. [PubChem]

Indication

For lowering intraocular pressure (IOP) and may be used in patients with chronic open-angle glaucoma or ocular hypertension.

Pharmacology

Levobunolol is an ophthalmic beta-blocker, equally effective at β(1)- and β(2)-receptor sites. Levobunolol reduces both elevated and normal IOP in patients with or without glaucoma. In patients with elevated IOP, levobunolol reduces mean IOP by approximately 25-40% from baseline. As the drug is a nonselective &beta-adrenergic blocking agent, it can produce both systemic pulmonary and cardiovascular effects following topical application to the eye. These effects include adverse pulmonary effects (eg. bronchoconstriction, increased airway resistance), and a decrease in blood pressure and heart rate.

Toxicity

Bradycardia, hypotension, bronchospasm, and acute cardiac failure, LD₅₀=700 mg/kg (orally in rat).

Affected Organisms

Biotransformation

Hepatic

Absorption

80%

Half Life

20 hours

References

External Links